ARS Pharmaceuticals (SPRY) Accumulated Expenses (2020 - 2026)

ARS Pharmaceuticals has disclosed Accumulated Expenses across 6 years of filings, most recently posting $20.4 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $20.4 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $20.4 million (changed N/A YoY), and the FY2025 annual result was $6.9 million, up 270.89% from the prior year.
• Accumulated Expenses came in at $20.4 million for Q1 2026 at ARS Pharmaceuticals, up from $6.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $20.4 million in Q1 2026 to a low of $282000.0 in Q3 2022.
• The 4-year median for Accumulated Expenses is $4.4 million (2024), against an average of $6.7 million.
• Across the five-year window, Accumulated Expenses plunged 93.82% in 2022 and jumped 270.89% in 2025, its largest moves.
• ARS Pharmaceuticals' Accumulated Expenses stood at $12.0 million in 2022, then slumped by 84.54% to $1.9 million in 2024, then surged by 270.89% to $6.9 million in 2025, then jumped by 196.67% to $20.4 million in 2026.
• The last three Accumulated Expenses figures came in at $20.4 million (Q1 2026), $6.9 million (Q4 2025), and $11.3 million (Q3 2025), per Business Quant data.